Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.

OBJECTIVE To investigate the relationship between acute-phase serum amyloid A (A-SAA) and joint destruction in inflammatory arthritis. METHODS Serum A-SAA and C-reactive protein (CRP) levels, the erythrocyte sedimentation rate (ESR), and levels of matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, MMP-9, MMP-13, tissue inhibitor of metalloproteinases 1 (TIMP-1), vascular endothelial growth factor (VEGF), and type I and type II collagen-generated biomarkers C2C and C1,2C were measured at 0-3 months in patients with inflammatory arthritis commencing anti-tumor necrosis factor α (anti-TNFα) therapy and were correlated with 1-year radiographic progression. The effects of A-SAA on MMP/TIMP expression on RA fibroblast-like synoviocytes (FLS), primary human chondrocytes, and RA/psoriatic arthritis synovial explant cultures were assessed using real-time polymerase chain reaction, enzyme-linked immunosorbent assay, antibody protein arrays, and gelatin zymography. RESULTS Serum A-SAA levels were significantly (P < 0.05) correlated with MMP-3, the MMP-3:TIMP-1 ratio, C1,2C, C2C, and VEGF. The baseline A-SAA level but not the ESR or the CRP level correlated with the 28-joint swollen joint count and was independently associated with 1-year radiographic progression (P = 0.038). A-SAA increased MMP-1, MMP-3, MMP-13, and MMP/TIMP expression in RA FLS and synovial explants (P < 0.05). In chondrocytes, A-SAA induced MMP-1, MMP-3, and MMP-13 messenger RNA and protein expression (all P < 0.01), resulting in a significant shift in MMP:TIMP ratios (P < 0.05). Gelatin zymography revealed that A-SAA induced MMP-2 and MMP-9 activity. Blockade of the A-SAA receptor SR-B1 (A-SAA receptor scavenger receptor-class B type 1) inhibited MMP-3, MMP-2, and MMP-9 expression in synovial explant cultures ex vivo. Importantly, we demonstrated that A-SAA has the ability to induce TNFα expression in RA synovial explant cultures (P < 0.05). CONCLUSION A-SAA may be involved in joint destruction though MMP induction and collagen cleavage in vivo. The ability of A-SAA to regulate TNFα suggests that A-SAA signaling pathways may provide new therapeutic strategies for the treatment of inflammatory arthritis.

[1]  P. Tak,et al.  Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo , 2010, PloS one.

[2]  B. Bresnihan,et al.  Acute Serum Amyloid A Induces Migration, Angiogenesis, and Inflammation in Synovial Cells In Vitro and in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model , 2010, The Journal of Immunology.

[3]  J. Raynes,et al.  The proinflammatory activity of recombinant serum amyloid A is not shared by the endogenous protein in the circulation. , 2010, Arthritis and rheumatism.

[4]  B. Bresnihan,et al.  A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A. , 2010, The American journal of pathology.

[5]  B. Bresnihan,et al.  Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies , 2009, Arthritis research & therapy.

[6]  F. Breedveld,et al.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial , 2008, The Lancet.

[7]  A. Karlsson,et al.  Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like‐1 , 2008, Journal of leukocyte biology.

[8]  J. Bylund,et al.  Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7‐sensitive pathway independent of formyl peptide receptor‐like 1 , 2008, Journal of leukocyte biology.

[9]  B. Bresnihan,et al.  Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. , 2007, Arthritis and rheumatism.

[10]  A. L. Jensen,et al.  Serum amyloid A isoforms in serum and synovial fluid from spontaneously diseased dogs with joint diseases or other conditions. , 2007, Veterinary immunology and immunopathology.

[11]  Chih-Hung Ku,et al.  Evaluation of Serum Amyloid A as a Biomarker for Gastric Cancer , 2006, Annals of Surgical Oncology.

[12]  B. Bresnihan,et al.  Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. , 2006, Arthritis and rheumatism.

[13]  K. Brandt,et al.  Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. , 2006, The Journal of rheumatology.

[14]  M. Abrahamowicz,et al.  Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis , 2006, Arthritis Research & Therapy.

[15]  Michael Kimelman,et al.  Serum Amyloid A Binding to CLA-1 (CD36 and LIMPII Analogous-1) Mediates Serum Amyloid A Protein-induced Activation of ERK1/2 and p38 Mitogen-activated Protein Kinases* , 2005, Journal of Biological Chemistry.

[16]  Chang Yeop Han,et al.  Thematic review series : The Immune System and Atherogenesis Lipoprotein-associated inflammatory proteins : markers or mediators of cardiovascular disease ? , 2005 .

[17]  S. van der Linden,et al.  Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change , 2004, Annals of the rheumatic diseases.

[18]  B. Bresnihan,et al.  Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. , 2004, Arthritis and rheumatism.

[19]  S. van der Linden,et al.  Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[20]  Alexander Fraser,et al.  Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. , 2003, Arthritis and rheumatism.

[21]  L. Kay,et al.  Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings. , 2003, Rheumatology.

[22]  A. Poole.  Can serum biomarker assays measure the progression of cartilage degeneration in osteoarthritis? , 2002, Arthritis and rheumatism.

[23]  L. Klareskog,et al.  Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. , 2002, Rheumatology.

[24]  P. Pussinen,et al.  Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line. , 2002, The international journal of biochemistry & cell biology.

[25]  N. Kamatani,et al.  A novel single-nucleotide polymorphism at the 5'-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[26]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[27]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[28]  A. Whitehead,et al.  Serum amyloid A, the major vertebrate acute-phase reactant. , 1999, European journal of biochemistry.

[29]  A. Zwinderman,et al.  Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. , 1999, Arthritis and rheumatism.

[30]  R. Barnard,et al.  Effect of diet on fat cell size and hormone-sensitive lipase activity. , 1999, Journal of applied physiology.

[31]  P. Emery,et al.  Synovial Cytokine and Growth Factor Regulation of MMPs/TIMPs: Implications for Erosions and Angiogenesis in Early Rheumatoid and Psoriatic Arthritis Patients , 1999, Annals of the New York Academy of Sciences.

[32]  J. Sipe,et al.  Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. , 1999, The Journal of rheumatology.

[33]  P. Shekelle,et al.  How to read radiographs according to the Sharp/van der Heijde method. , 1999 .

[34]  F. Breedveld,et al.  Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. , 1998, Arthritis and rheumatism.

[35]  C. Rorabeck,et al.  Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. , 1995, The Journal of clinical investigation.

[36]  N. Fujimoto,et al.  Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[37]  D. Veale,et al.  Classification of clinical subsets in psoriatic arthritis. , 1994, British journal of rheumatology.

[38]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[39]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[40]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[41]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[42]  G. R. Dodge,et al.  Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. , 1989, The Journal of clinical investigation.

[43]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[44]  G. Coetzee,et al.  Identification of three isoform patterns of human serum amyloid A protein. , 1988, The Biochemical journal.

[45]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[46]  B. Bresnihan,et al.  Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. , 2006, Arthritis and rheumatism.

[47]  Michael J. Green,et al.  Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. , 2003, Rheumatology.

[48]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[49]  B. Bresnihan,et al.  Serum amyloid A in the assessment of early inflammatory arthritis. , 2000, The Journal of rheumatology.

[50]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[51]  Mauro Alini,et al.  9 – Cellular Biology of Cartilage Degradation , 1995 .